Pegylated Interferon(Peg-IFN) in Reducing Relapse Rate in Patients After Discontinuation of NUC Therapy
Status:
Unknown status
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
This study evaluates whether Peg-IFN alfa-2a can reduce the recurrence rate of hepatitis B in
96 weeks after nucleoside analogue (NUC) withdrawal.
The HBV HBeAg-Negative patients who received NUC anti-virus treatment for 2.5 years and
reached stopping rule in 《Chinese chronic hepatitis B prevention and treatment
guidelines》(2010) were randomly assigned into three groups: One group discontinue the NUC
treatment and follow up for 96 weeks,One discontinue the NUC treatment ,receive Peg-IFN
alfa-2a 180 μg by week for 24 weeks and follow up for 72 weeks,The other discontinue the NUC
treatment ,receive Peg-IFN alfa-2a 180 μg by week for 48 weeks and follow up for 48 weeks.